Forbes Daily Briefing

Tyler Shultz, a former Theranos employee who blew the whistle on the ill-fated biotech company, alleged its founder and convicted fraudster Elizabeth Holmes “misled” Nathan Fielder about the technology her company developed in a key scene in his new documentary, “You Can See Everything.”

Read the full story on Forbes: https://www.forbes.com/sites/conormurray/2026/10/19/theranos-whistleblower-alleges-elizabeth-holmes-misled-nathan-fielder-in-documentary-scene/
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Chinese-owned social network has run dozens of ads promoting the sale of counterfeit currency. One even directed users to a Telegram account offering a discount code for 10% off fake money: “TikTok10.”
Learn more about your ad choices. Visit megaphone.fm/adchoices

Stephen Curry was the NBA’s first unanimous MVP, in 2016. The first player to lead the league in 3-pointers four times, then five times, then six and seven and eight times. The first player to launch 10,000 attempts from beyond the arc—and the first to drain 4,000 of them.

But for all of the ways the Golden State Warriors’ 38-year-old sharpshooter has transformed basketball, he is just as much of a game-changer financially.

Already the first NBA player with a $40 million salary (in 2019-20) and a $50 million salary (2023-24), Curry is set to cross the $60 million threshold this season, banking $62.6 million on the court. Meanwhile, after splitting with his longtime sponsor Under Armour last fall and unveiling a new deal with Chinese shoe brand Li-Ning in June, Curry projects to earn an estimated $141 million from endorsements and other business endeavors—demolishing the NBA-record $100 million he made off the court in 2024-25.

Read the full story on Forbes: https://www.forbes.com/sites/brettknight/2026/10/20/highest-paid-nba-players-2026-curry-is-basketballs-first-200-million-man/

Learn more about your ad choices. Visit megaphone.fm/adchoices

IN SEPTEMBER 2025, staff from an environmental nonprofit descended on Trump National Golf Club in Jupiter, Florida. Over three days, they looked for the kind of things that excite naturalists—bird species, bat calls, plant varieties—then recorded their discoveries in a 180-page report. It barely mentioned the thing they were really looking for: a tax break for Donald Trump.

The president needed one, desperately. Trump’s return to the White House, and his eagerness to profit from it, yielded $1.4 billion of crypto earnings in 2025. His real-estate empire supplied more than $200 million on top of that, according to Forbes calculations. The president’s projected tax bill snowballed to over $500 million.

Enter the environmentalists. Among the many peculiarities of the U.S. tax code is a provision allowing landowners to cut their bills by giving up development rights—even if they retain the land itself. The premise is straightforward: Forgoing development can preserve natural habitats, a public benefit that can qualify as a charitable gift. The 180-pager made the case that Trump’s golf course qualified as a natural habitat worth protecting. He then donated the right to further develop it to an environmental nonprofit—without giving up ownership of the golf club itself.

Read the full story on Forbes: https://www.forbes.com/sites/danalexander/2026/10/19/trumps-golf-empire-is-a-billion-dollar-tax-shelter/
Learn more about your ad choices. Visit megaphone.fm/adchoices

As CEO of the largest, most successful drugmaker on the planet, Dave Ricks sure spends a lot of time thinking about risk.

Eli Lilly’s weight-loss and diabetes drugs have become wildly successful beyond anyone’s imagination. Its latest 12-month revenue (through June 30) surged 50% to $79.7 billion, with Zepbound (for weight loss) and Mounjaro (for diabetes) accounting for 62% of the total. In November 2025, its market cap crossed the $1 trillion mark, making it the first pharma company to do so (it’s currently hovering around $1.1 trillion).

Lilly has more weight-loss game-changers coming. A pill called Foundayo gained FDA approval in April. It plans to submit a next-gen experimental drug, retatrutide, to the FDA in the first quarter of 2027. (People are so excited about “reta,” as it’s called online, that they’re buying substances claiming to be the drug on the black market.)

But the clock is ticking. All drugs have a shelf life because of how pharma patents work. Likely at some point in the 2030s, the exploding market for its weight-loss drugs will collapse as generics flood in.

Read the full story on Forbes: https://www.forbes.com/sites/amyfeldman/2026/10/15/glp-1s-took-eli-lilly-to-1-trillion-ceo-dave-ricks-is-betting-billions-he-can-do-it-again/
Learn more about your ad choices. Visit megaphone.fm/adchoices